- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
Chemotherapy Research and Practice
Volume 2013 (2013), Article ID 547932, 7 pages
Self-Management of Oxaliplatin-Related Peripheral Neuropathy in Colorectal Cancer Survivors
1University of South Florida College of Nursing in Tampa, FL 33612, USA
2University of Massachusetts Boston, Boston, MA 02125, USA
3Dana Farber Cancer Institute, Boston, MA 02215, USA
4University of Central Florida, Orlando, FL 32816, USA
Received 30 April 2013; Accepted 23 July 2013
Academic Editor: Umberto Tirelli
Copyright © 2013 Cindy Tofthagen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Purpose. The purpose of this study was to evaluate medications that cancer survivors with oxaliplatin-induced peripheral neuropathy take to control neuropathic symptom, and to explore self-management techniques used at home to provide temporary relief of painful neuropathy. This was a mixed methods, descriptive, cross-sectional study using self-reported data from colorectal cancer survivors previously treated with oxaliplatin. We analyzed demographic and medication data obtained from participants, along with written comments from an open-ended question regarding methods participants had tried to self-manage symptoms of neuropathy. Results. Twenty-nine percent of the sample reported taking some type of nutritional supplement with potential neuroprotective qualities. Opioids were being taken by 10% of the sample, and nonsteroidal anti-inflammatory and over-the-counter medications were taken by 15% of participants. Twelve percent of participants were taking antidepressants and 10% were taking anticonvulsants, primarily gabapentin. Recurrent themes for nonpharmacologic treatment included avoiding the cold/keeping warm, keeping moving, massaging or rubbing the affected area, and living with it. Conclusions. Patients treated with oxaliplatin for colorectal cancer utilize a variety of traditional pharmacologic agents and nutritional supplements in an effort to self-manage neuropathic symptoms. Patients also employ a variety of home-based therapies to provide temporary relief of peripheral neuropathy symptoms.
Oxaliplatin is a highly neurotoxic chemotherapy drug routinely used to treat colorectal cancer in the adjuvant and metastatic disease settings . Among the approximately 100,000 persons diagnosed with colon cancer each year, approximately 60% will be candidates to receive oxaliplatin-based chemotherapy . At least 48% of patients who receive oxaliplatin will develop chronic peripheral neuropathy that arises during treatment, and still more patients will go on to develop chronic neuropathy after cessation of treatment, a phenomenon known as “coasting” [3–6].
Few evidence-based interventions exist for treatment of oxaliplatin-related neuropathy [7–9]. Supportive care for peripheral neuropathy includes pain management, fall prevention, home safety education, provision of psychological support, measures to enhance or maintain physical functioning, and recommendations for assistive devices to help with daily activities . In clinical practice, the focus of management of peripheral neuropathy is primarily aimed at control of neuropathic pain. Agents such as anticonvulsants, antidepressants, and opioids are commonly prescribed for treatment of neuropathic pain in individuals with peripheral neuropathy. However, untoward side effects such as somnolence and weight gain may result in poor adherence [11, 12]. A lack of understanding concerning the treatment regimen may result in patients taking anticonvulsants and antidepressants on an as-needed basis, instead of around the clock, as normally prescribed for neuropathic pain, resulting in ineffective pain control. Frequent titration of medications prescribed for neuropathic pain is required to achieve adequate pain control but patient-provider communication often breaks down before optimal dosing is achieved [13–15].
Although calcium and magnesium infusions may help prevent development of oxaliplatin-related peripheral neuropathy [16–19], data supporting use of other nutritional supplements for either prevention or treatment of oxaliplatin-induced peripheral neuropathy is sparse [20–22]. However, well-meaning clinicians, in the absence of other tolerable and effective treatments, may recommend a variety of nutritional supplements, including vitamin E, B vitamins, alpha lipoic acid, acetyl-L-carnitine, and oral calcium and magnesium to patients seeking relief from symptoms of peripheral neuropathy. Patients also may self-prescribe nutritional supplements because they are readily available and perceived to be harmless or relatively free of side effects.
Patients may also try a variety of nonpharmacologic methods at home to relieve their neuropathy symptoms, with varying degrees of success. Previous work in persons with acquired immune deficiency syndrome (AIDS) related neuropathy suggests that taking hot baths, resting from activity, applying foot cream, elevating feet, and exercising may provide temporary relief of painful neuropathy [23, 24]. Similar research about self-management strategies has been conducted in breast cancer patients receiving taxane chemotherapy. Results demonstrate that patients developed varied, individual coping strategies for each impacted activity such as driving, walking, socializing, cooking, balance, sleeping, and work. These interventions included manipulating their movements (walking slowly), making changes within their environment to prevent exacerbation of symptoms (taking baths instead of showers), and maintaining a positive attitude .
Our research team previously described persistent problems with peripheral neuropathy and associations between peripheral neuropathy, health-related quality of life, sleep disturbance, and depressive symptoms in colorectal cancer survivors as far as 7 years after treatment . The purpose of this study was to evaluate medications that cancer survivors with oxaliplatin-induced peripheral neuropathy take to control neuropathic symptoms and to explore self-management techniques that participants used at home to provide temporary relief of painful neuropathy.
2.1. Study Design
This was a descriptive, cross-sectional study using self-reported data from colorectal cancer survivors previously treated with oxaliplatin-based chemotherapy. To conduct this analysis, we used demographic and medication data obtained from participants, along with written comments from an open-ended question regarding methods participants had tried to self-manage symptoms of neuropathy.
2.2. Sample and Setting
Men and women with a history of stage III-IV colorectal cancer treated with oxaliplatin at the Moffitt Cancer Center between 1 and 8 years before enrollment were included in this study. Diabetics and individuals with preexisting neuropathy (before receiving chemotherapy) were excluded from the study. To be eligible for the study, participants met the following eligibility criteria:(1)at least 18 years of age; treated with oxaliplatin for stage III-IV colorectal cancer;(2)no documented or psychiatric or neurologic disorders that would interfere with study participation;(3)able to speak and read standard English;(4)provide informed consent.
The study was approved by the Institutional Review Board at the University of South Florida and patients were identified through the Moffitt Cancer Center Cancer Registry. Survivors meeting the study criteria were contacted by telephone to confirm eligibility and to obtain informed verbal consent. Enrolled participants were mailed a study packet and a postage paid return envelope. Approximately 1 week later, those survivors who had not yet returned the packet were contacted by telephone and prompted to complete and return the material. A total of 128 survivors agreed to participate. Of these, 111 (94%) survivors completed and returned the study packet.
Demographic data were obtained via a standard self-report questionnaire. Demographic variables included gender, age, race/ethnicity, annual household income, educational level, and marital status. Participants were asked to provide a list of all current medications and to provide an open-ended response to the following question: “If you have numbness, tingling, or discomfort in your hands or feet, muscle weakness, joint or muscle pain, or loss of balance, what have you tried to relieve your symptoms? How helpful was it?” Questionnaires that were also completed by participants and reported on in an earlier publication included a modified version of the Chemotherapy-Induced Peripheral Neuropathy Assessment Tool , the Center for Epidemiological Studies-Depression Scale (CES-D) , the Insomnia Severity Index (ISI) , and the Medical Outcomes Study Short Form-36 . Medical data were reviewed at the completion of study participation to obtain information about the number of cycles and cumulative doses of oxaliplatin; however, cycle number and dosing information were not available for the majority of participants.
3.1. Data Analysis
Qualitative descriptive methodology, with the written narrative responses as the method of inquiry, was used to explore the medications and home-based strategies used by colorectal cancer survivors in the self-management of oxaliplatin-related peripheral neuropathy. This analytic strategy was chosen since little is known about self-management of oxaliplatin-related peripheral neuropathy, and thus, descriptive information is needed .
Qualitative data were analyzed using Atlas Ti , a qualitative data management software package used for categorization, thematic coding, and assessment of meanings and relationships within text. Transcripts were proof-read, reviewed for accuracy, and coded and sorted into categories reflecting significant elements of the responses. Categories were coded into themes and subthemes . Codes and categories were checked for accuracy by the researcher and colleagues (oncology researcher and qualitative researcher) to ensure accuracy and to increase validity.
Medications were examined to identify those commonly used for treatment of neuropathic pain (anticonvulsants, antidepressants, opioids, and nonsteroidal anti-inflammatories) or are purported to offer some degree of neuroprotection (nutritional supplements). These medications were categorized and descriptive statistics including frequencies and percentages were analyzed using Microsoft Excel software. Two researchers conducted independent analyses of the medication data to confirm accuracy of results.
A total of 128 survivors agreed to participate. 111 (94%) survivors completed and returned the study packet and 105 (82%) provided a list of current medications including over-the-counter medications and nutritional supplements. Seventy percent () provided written comments regarding what they have tried for neuropathy (70%). The sample was 51% male, 88% Caucasian, 71% stage 3-colon cancer, and 37% still employed (not retired or disabled) . Time since beginning oxaliplatin-based chemotherapy ranged from 1 to 7 years with a mean of 3 years since oxaliplatin-based chemotherapy was initiated.
Twenty-nine percent () of the sample reported taking some type of nutritional supplement with potential neuroprotective qualities. B-vitamins, alpha lipoic acid, acetyl-L-carnitine, L-glutamine, Bing Ling Herbals, omega-3 fatty acids, oral calcium, and magnesium were among the nutritional supplements used. Opioids were being taken by 10% (), and nonsteroidal anti-inflammatory and over-the-counter medications such as acetaminophen or ibuprofen were taken by 15% () of participants. Twelve percent of participants () were taking antidepressants and 10% () were taking anticonvulsants, primarily gabapentin. Recurrent themes for nonpharmacologic treatment included avoiding the cold/keeping warm, keeping moving, massaging or rubbing the affected area, and living with it. Table 1 contains quotes pertinent to recurrent identified themes. In addition to the themes identified and data of medication use, participants made reference to the use of general health maintenance strategies such as “eat healthy, light exercise, and keep emotionally calm.” Participants also mentioned the use of acupuncture and anodyne light therapy as self-management strategies they had tried at home to help alleviate symptoms.
This study examines specific medication and self-care strategies for the treatment of oxaliplatin-based peripheral neuropathy in colorectal cancer survivors. Participants in this study employed a variety of complementary and alternative approaches to control neuropathic symptoms, which are similar to the self-care strategies reported by patients of earlier studies with AIDS-related neuropathy and those receiving taxanes [23, 24].
Relatively few participants were taking anticonvulsants or antidepressants, which are considered first-line treatment for neuropathic pain [13–15]. Similarly, Gharibian et al. (2013)  found that patients taking antidepressants or anticonvulsants for neuropathic pain had less than a 45% compliance rate and that less than 25% consistently refilled their prescriptions for these drugs. Reasons patients may choose not to take these classes of medications for treatment of neuropathic pain may include low tolerability, perceived risks associated with these medications, lack of perceived benefit, misunderstanding of how antidepressants or anticonvulsants can be helpful, or confusion regarding dosing and need for dose escalation. A limitation of this study is that its cross-sectional design does not allow for examining patterns in use of medications over time or provide insight as to how many participants had been prescribed medications but elected either not to take them at all or to discontinue them.
Nutritional supplements were more frequently taken by participants than any other type of medication we examined, even though there is limited empirical evidence to support the use of any specific nutritional supplements for treatment of existing neuropathy in cancer survivors. We do not know whether these were recommended by a healthcare provider or whether patients independently sought out information on the use of nutritional supplements. Patients may seek alternative forms of treatment when they perceive that the risks and side effects associated with standard medical treatments are too high or that available treatments are of limited benefit, although we did not specifically collect data regarding the reason they were taking.
5.2. Self-Care Strategies
Participants reported that cold temperatures exacerbated painful neuropathies, caused stiffness, and further impaired physical functioning. Self-management strategies for keeping the affected areas warm were often utilized. Wearing gloves and socks, running hot water over the affected areas, use of heating pads, and drinking warm liquids were strategies that patients used to keep warm. Primarily, symptoms associated with cold temperatures, including dysphonia, laryngospasm, and electric shock sensation when touching a cold object, have been associated with acute oxaliplatin neurotoxicity . Our data indicates that cold temperatures may also increase symptoms of neuropathy well past the acute treatment phase, and suggesting methods to keep the entire body warm as well as the affected extremities may help to minimize neuropathy symptoms on a temporary basis. However, the data from this study does not permit an analysis of how effectively keeping the affected areas warm may have mitigated neuropathic symptoms.
Cold-induced neuropathic symptoms may not follow classic distal to proximal distribution. One participant described symptoms in the hands but none in the feet; “I have numbness in my fingertips only when they get cold. I have muscle weakness in my fingers (doing things like opening lids, containers, writing, etc.) when they are cold. The weakness is significant. I have a decrease in fine motor skills when my fingers are cold. At normal temperatures, I have no symptoms. It is a definite change in how they were prior to the chemo. My feet are fine I have no remaining symptoms.” Some patients obtained temporary relief by massaging or rubbing the affected area of the body and others reported a feeling that there was little in the way of medical or self-management that provided substantial benefit, concluding that neuropathy is something that they must learn to cope with and endure.
Participants reported using various types of physical activity and exercise to help alleviate peripheral neuropathy symptoms to permit them to function at prechemotherapy levels. Participants described utilizing general physical activities and exercise such as yoga, swimming, biking, jogging or running, lifting weights, walking, golfing, physical therapy, a period. Some participants provided more specific descriptions of their exercise regimens including “Maintained prechemotherapy fitness program by jogging 1.5–2 miles 3 times a week” and “for balance, practice standing on one leg and alternating legs.”
Exercise can be safely recommended to patients with neuropathy, specifically those suffering from impaired balance , but as with other cancer-related symptoms, patients may benefit from having specific recommendations for type of exercise, dose, and frequency. Recommendations for referral to physical therapy may be warranted as well as beneficial in assisting patients to maintain or regain functional performance levels after treatment with oxaliplatin. While there is a potential role for physical activity and exercise in the management of peripheral neuropathy, the types of activities and exercise that may be most beneficial, frequency, and duration are not known. Further research of physical activity and exercise is critically needed, as pharmacologic strategies for managing peripheral neuropathy have not proven universally successful.
Although strategies like massage, pain medication, and application of heat may provide temporary symptom relief, participants also expressed the feeling that there was little they could do to relieve their symptoms, a view that may have been supported by healthcare providers in some cases. One participant wrote “Doctor said there is no cure or relief.” Another participant expressed gratitude for ongoing research in the area with the following statement included with the questionnaire packet, “Thank you so much for pursuing this research. I have asked to speak with Sanofi research and development to advise them of the profound side effects post oxaliplatin. I have had no response from them. Thank you for this research, my internet research only gives outcome date up to 2 years after treatment. I sense there are many clients that have profound chemo deficits long after 2 years.”
Patients treated with oxaliplatin for colorectal cancer utilize traditional pharmacologic agents and nutritional supplements in an effort to self-manage neuropathic symptoms. Patients also employ a variety of home-based therapies to provide temporary relief of peripheral neuropathy symptoms, with minimum efficacy. It is clear that patients want and need strategies to assist them with self-management of neuropathic consequences of cancer treatment. Future research testing the various means of self-management, including massaging, keeping the affected area warm, and generating “whole body” warmth and comfort, is indicated. Additionally, the development and testing of a sequential approach to the self-management of oxaliplatin-related neuropathy may be helpful in identifying which strategies are appropriate sooner after treatment as opposed to those that may be more effective when “coasting” of the chemotherapeutic agent has taken place. Additional research is needed to identify new methods of managing symptoms of oxaliplatin-related neuropathy at home that will provide effective symptom relief as well as be acceptable and tolerable to patients.
This study was supported by the University of South Florida Nursing Faculty in Pilot Research Projects Grant and the University of Massachusetts Boston-Dana Farber/Harvard Cancer Center U54 Cancer Research Partnership.
- FDA, “FDA Approval for Oxaliplatin,” 2006 http://www.cancer.gov/cancertopics/druginfo/fda-oxaliplatin.
- ACS, “Cancer facts & figures 2012,” 2012 http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-031941.pdf.
- A. Grothey, “Oxaliplatin-safety profile: neurotoxicity,” Seminars in Oncology, vol. 30, no. 4, supplement 15, pp. 5–13, 2003.
- J. Choi, K. Kong, T. Mozaffar, and R. F. Holcombe, “Delayed oxaliplatin-associated neurotoxicity following adjuvant chemotherapy for stage III colon cancer,” Anti-Cancer Drugs, vol. 17, no. 1, pp. 103–105, 2006.
- A. A. Argyriou, P. Polychronopoulos, G. Iconomou, E. Chroni, and H. P. Kalofonos, “A review on oxaliplatin-induced peripheral nerve damage,” Cancer Treatment Reviews, vol. 34, no. 4, pp. 368–377, 2008.
- L. M. Alejandro, C. E. Behrendt, K. Chen, H. Openshaw, and S. Shibata, “Predicting acute and persistent neuropathy associated with oxaliplatin,” American Journal of Clinical Oncology, vol. 36, no. 4, pp. 331–337, 2012.
- C. Visovsky, M. Collins, L. Abbott, J. Aschenbrenner, and C. Hart, “Putting evidence into practice: evidence-based interventions for chemotherapy-induced peripheral neuropathy,” Clinical journal of oncology nursing, vol. 11, no. 6, pp. 901–913, 2007.
- E. M. L. Smith, S. L. Beck, and J. Cohen, “The total neuropathy score: a tool for measuring chemotherapy-induced peripheral neuropathy,” Oncology Nursing Forum, vol. 35, no. 1, pp. 96–102, 2008.
- E. M. L. Smith, J. A. Cohen, M. A. Pett, and S. L. Beck, “The reliability and validity of a modified total neuropathy score-reduced and neuropathic pain severity items when used to measure chemotherapy-induced peripheral neuropathy in patients receiving taxanes and platinums,” Cancer Nursing, vol. 33, no. 3, pp. 173–183, 2010.
- C. Tofthagen, C. Visovsky, and R. Hopgood, “Chemotherapy-induced peripheral neuropathy: an algorithm to guide nursing management,” Clinical Journal of Oncology Nursing, vol. 17, no. 2, pp. 138–144, 2013.
- D. Gharibian, J. K. Polzin, and J. P. Rho, “Compliance and persistence of antidepressants versus anticonvulsants in patients with neuropathic pain during the first year of therapy,” Clinical Journal of Pain, vol. 29, no. 5, pp. 377–381, 2013.
- A. O. Oladapo, J. C. Barner, K. L. Rascati, and S. A. Strassels, “A retrospective database analysis of neuropathic pain and oral antidiabetic medication use and adherence among texas adults with type 2 diabetes enrolled in medicaid,” Clinical Therapeutics, vol. 34, no. 3, pp. 605–613, 2012.
- D. E. Moulin, A. J. Clark, I. Gilron et al., “Pharmacological management of chronic neuropathic pain—consensus statement and guidelines from the canadian pain society,” Pain Research and Management, vol. 12, no. 1, pp. 13–21, 2007.
- R. H. Dworkin, A. B. O'Connor, J. Audette et al., “Recommendations for the pharmacological management of neuropathic pain: An overview and literature update,” Mayo Clinic Proceedings, vol. 85, no. 3, pp. S3–S14, 2010.
- N. Attal, G. Cruccu, R. Baron et al., “EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision,” European Journal of Neurology, vol. 17, no. 9, pp. 1113–1123, 2010.
- R. Ao, Y. H. Wang, R. W. Li, and Z. R. Wang, “Effects of calcium and magnesium on acute and chronic neurotoxicity caused by oxaliplatin: a meta-analysis,” Experimental and Therapeutic Medicine, vol. 4, no. 5, pp. 933–937, 2012.
- Z. Wu, J. Ouyang, Z. He, and S. Zhang, “Infusion of calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in colorectal cancer: a systematic review and meta-analysis,” European Journal of Cancer, vol. 48, no. 12, pp. 1791–1798, 2012.
- A. Grothey, D. A. Nikcevich, J. A. Sloan et al., “Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7,” Journal of Clinical Oncology, vol. 29, no. 4, pp. 421–427, 2011.
- L. Gamelin, M. Boisdron-Celle, A. Morel et al., “Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusion and no impact on its efficacy,” Journal of Clinical Oncology, vol. 26, no. 7, pp. 1188–1189, 2008.
- L. A. Kottschade, J. A. Sloan, and C. L. Loprinzi, “Response to letter to the editor referencing manuscript the ‘use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial‘,” Supportive Care in Cancer, vol. 19, no. 5, pp. 727–728, 2011.
- P. Lin, M. Lee, W. Wang et al., “N-acetylcysteine has neuroprotective effects against oxaliplatin-based adjuvant chemotherapy in colon cancer patients: preliminary data,” Supportive Care in Cancer, vol. 14, no. 5, pp. 484–487, 2006.
- E. K. Joseph, X. Chen, O. Bogen, and J. D. Levine, “Oxaliplatin acts on IB4-positive nociceptors to induce an oxidative stress-dependent acute painful peripheral neuropathy,” Journal of Pain, vol. 9, no. 5, pp. 463–472, 2008.
- P. K. Nicholas, J. K. Kemppainen, G. E. Canaval et al., “Symptom management and self-care for peripheral neuropathy in HIV/AIDS,” AIDS Care, vol. 19, no. 2, pp. 179–189, 2007.
- P. K. Nicholas, J. Voss, D. Wantland et al., “Prevalence, self-care behaviors, and self-care activities for peripheral neuropathy symptoms of HIV/AIDS,” Nursing and Health Sciences, vol. 12, no. 1, pp. 119–126, 2010.
- R. M. Speck, A. DeMichele, J. T. Farrar et al., “Scope of symptoms and self-management strategies for chemotherapy-induced peripheral neuropathy in breast cancer patients,” Supportive Care in Cancer, vol. 20, no. 10, pp. 2433–2439, 2012.
- C. Tofthagen, K. A. Donovan, M. A. . Morgan, D. Shibata, and Y. Yeh, “Oxaliplatin-induced peripheral neuropathy's effects on health-related quality of life of colorectal Cancer survivors,” Supportive Care in Cancer. In press.
- C. S. Tofthagen, S. C. McMillan, and K. E. Kip, “Development and psychometric evaluation of the chemotherapy-induced peripheral neuropathy assessment tool,” Cancer Nursing, vol. 34, no. 4, pp. E10–E20, 2011.
- L. S. Radloff, “The CES-D scale: a self report depression scale for research in the general population,” Applied Psychological Measurements, vol. 1, pp. 385–401, 1977.
- C. M. Morin, Insomnia: Psychological Assessment and Management, Guilford Press, New York, NY, USA, 1993.
- J. E. Ware Jr. and C. D. Sherbourne, “The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection,” Medical Care, vol. 30, no. 6, pp. 473–483, 1992.
- M. Sandelowski, “What's in a name? Qualitative description revisited,” Research in Nursing and Health, vol. 33, no. 1, pp. 77–84, 2010.
- “ATLAS.ti version 6.2. [Computer sofware],” Scientific Sofware Development: Berlin, Germany, 2013.
- M. Sandelowski and J. Leeman, “Writing usable qualitative health research findings,” Qualitative Health Research, vol. 22, no. 10, pp. 1404–1413, 2012.
- M. Berretta, R. Taibi, A. Bearz et al., “Dysphonia as an unusual toxic event of oxaliplatin-based chemotherapy,” Journal of Chemotherapy, vol. 16, no. 6, pp. 595–598, 2004.
- C. Tofthagen, C. Visovsky, and D. L. Berry, “Strength and balance training for adults with peripheral neuropathy and high risk of fall: current evidence and implications for future research,” Oncology Nursing Forum, vol. 39, no. 5, pp. E416–E424, 2012.